Stock 512 GRAND PHARMACEUTICAL GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Grand Pharmaceutical Group Limited

Equities

512

BMG210A71016

Pharmaceuticals

Delayed Hong Kong S.E.
Other stock markets
 02:01:02 2024-05-22 am EDT 		5-day change 1st Jan Change
4.85 HKD -3.39% Intraday chart for Grand Pharmaceutical Group Limited -3.96% +18.58%
Apr. 29 Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump MT
Mar. 27 Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 14,321 24,421 22,930 16,225 14,394 17,579 - -
Enterprise Value (EV) 1 14,321 24,421 22,930 16,225 14,394 17,579 17,579 17,579
P/E ratio - - - - 7.63 x 7.97 x 6.97 x 6.2 x
Yield - - - 3.04% 6.36% 6.18% 5.78% 6.57%
Capitalization / Revenue 2.17 x 3.84 x 2.67 x 1.7 x 1.37 x 1.47 x 1.29 x 1.17 x
EV / Revenue 2.17 x 3.84 x 2.67 x 1.7 x 1.37 x 1.47 x 1.29 x 1.17 x
EV / EBITDA - 10,116,064 x 7,124,918 x - - - - -
EV / FCF - - 14.9 x 13.3 x - 9.35 x 12.3 x 8.92 x
FCF Yield - - 6.69% 7.5% - 10.7% 8.15% 11.2%
Price to Book - - 1.71 x 1.14 x 0.94 x 1.09 x 1 x 0.91 x
Nbr of stocks (in thousands) 3,377,571 3,549,571 3,549,571 3,527,141 3,519,271 3,501,810 - -
Reference price 2 4.240 6.880 6.460 4.600 4.090 5.020 5.020 5.020
Announcement Date 3/27/20 4/28/21 3/17/22 3/22/23 3/19/24 - - -
1HKD in Million2HKD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 6,591 6,353 8,598 9,562 10,530 11,948 13,584 15,008
EBITDA - 2,414 3,218 - - - - -
EBIT 1 1,383 2,127 2,879 2,654 2,549 2,769 3,159 3,581
Operating Margin 20.98% 33.48% 33.48% 27.76% 24.21% 23.18% 23.26% 23.86%
Earnings before Tax (EBT) 1 - - - - 2,344 2,709 3,091 3,506
Net income 1 - - - - 1,880 2,229 2,540 2,880
Net margin - - - - 17.85% 18.66% 18.7% 19.19%
EPS 2 - - - - 0.5360 0.6300 0.7200 0.8100
Free Cash Flow 1 - - 1,534 1,216 - 1,881 1,433 1,970
FCF margin - - 17.84% 12.72% - 15.74% 10.55% 13.13%
FCF Conversion (EBITDA) - - 47.67% - - - - -
FCF Conversion (Net income) - - - - - 84.39% 56.42% 68.4%
Dividend per Share 2 - - - 0.1400 0.2600 0.3100 0.2900 0.3300
Announcement Date 3/27/20 4/28/21 3/17/22 3/22/23 3/19/24 - - -
1HKD in Million2HKD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - 1,534 1,216 - 1,881 1,433 1,970
ROE (net income / shareholders' equity) - 18.3% 19.5% 15.1% 12.8% 14% 14% 15%
ROA (Net income/ Total Assets) - 11.6% 12.6% - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - 3.770 4.020 4.330 4.590 5.010 5.500
Cash Flow per Share - - - - - - - -
Capex 1 566 209 472 626 - 600 800 1,000
Capex / Sales 8.59% 3.29% 5.48% 6.55% - 5.02% 5.89% 6.66%
Announcement Date 3/27/20 4/28/21 3/17/22 3/22/23 3/19/24 - - -
1HKD in Million2HKD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Grand Pharmaceutical Group Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.02
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GRAND PHARMACEUTICAL GROUP LIMITED Stock Grand Pharmaceutical Group Limited
+18.58% 2.25B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+37.78% 723B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.82% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.51% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.94% 331B
ABBVIE INC. Stock AbbVie Inc.
+5.14% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.64% 244B
ROCHE HOLDING AG Stock Roche Holding AG
-4.13% 208B
NOVARTIS AG Stock Novartis AG
+10.63% 210B
AMGEN INC. Stock Amgen Inc.
+9.32% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 512 Stock
  4. Financials Grand Pharmaceutical Group Limited
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW